Daclatasvir is an orally available inhibitor of the hepatitis C virus (HCV) non-structural protein 5A (NS5A) replication complex, with potential activity against HCV. Daclatasvir use with Sofosbuvir with or without Ribavirin to treat HCV genotype 1 and 3 infections. Daclatasvir was FDA-approved in July 2015.
FCE pharma is highly acclaimed and much anticipanted event for pharmaceutical industry in Latin America. SynZeal will be presenting at FCE Pharma 21 at Booth No G-083 during this event scheduled on Nov 30- Dec 02, 2021 at Sao Paulo Expo, Brazil.
Dabigatran is a direct inhibitor of thrombin and anticoagulant which is used for prevention of stroke and venous embolism in patients with chronic atrial fibrillation. Dabigatran was approved for medical use in 2010.
